# Open Label Extension Study of [S,S]-Reboxetine in Patients With Fibromyalgia

> **NCT00754221** · PHASE3 · TERMINATED · sponsor: **Pfizer** · enrollment: 390 (actual)

## Conditions studied

- Fibromyalgia

## Interventions

- **DRUG:** [S,S]-Reboxetine

## Key facts

- **NCT ID:** NCT00754221
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-05
- **Primary completion:** 2009-05
- **Final completion:** 2009-05
- **Target enrollment:** 390 (ACTUAL)
- **Why stopped:** This study has been terminated early as the esreboxetine development program is being discontinued. There are no safety or efficacy concerns.
- **Last updated:** 2019-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00754221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00754221, "Open Label Extension Study of [S,S]-Reboxetine in Patients With Fibromyalgia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00754221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*